Author | Age | Group | Type of lymphangiectasia | Intestinal involve | 3rd space involve | Response to diet therapy | Type of 2nd-line therapy | Results of 2nd-line therapy |
---|---|---|---|---|---|---|---|---|
CP Chen et al. (2003) [24] | 49 yr. | 1 | Focal intestine | Focal | No | No | Surgical resection | Remission |
L Zhu et al. (2010) [32] | 22 yr. | 1 | Focal intestine | Focal | No | Limited data | Surgical resection | Remission |
44 yr. | 1 | Focal intestine | Focal | No | Limited data | Surgical resection | Remission | |
71 yr. | 1 | Focal intestine | Focal | No | Limited data | Surgical resection | Remission | |
55 yr. | 1 | Focal intestine | Focal | No | Limited data | Surgical resection | Remission | |
W Kneist et al. (2013) [25] | 58 yr. | 1 | Focal intestine | Focal | No | No | Surgical resection | Remission |
J Mari et al. (2019) [28] | 10 yr. | 1 | Focal intestine | Focal | No | Limited data | Surgical resection | Remission |
G Kuroiwa et al. (2001) [26] | 21 yr. | 1 | Focal intestine | Focal | No | No | Octreotide | Recurred after discontinuation |
L Filk et al. (2004) [34] | 25 yr | Limited data | Limited data | Limited data | Limited data | No | Octreotide | Clinical improvement |
S Sari et al. (2010) [30] | N = 6, age 2–24 mo. | Limited data | Limited data | Limited data | Limited data | No | Octreotide | Clinical improvement |
Suehiro et al. (2012) [22] | 63 yr. | 1 | Focal intestine | Focal | No | No | Octreotide | Clinical improvement |
MJ Alshikho et al.(2016) [35] | 24 yr | Limited data | Limited data | Limited data | Limited data | No | Coconut oil + Octreotide | Clinical improvement |
Troskot et al. (2015) [31] | 42 yr. | 2 | Diffuse intestine | Diffuse | No | No | Octreotide | Clinical improvement |
Z Altın et al. (2018) [2] | 34 yr. | 3 | Extensive | limited | Yes | No | Octreotide | Recurred after discontinuation |
Acer-Demir et al. (2020) [23] | 3 yr. | 3 | Extensive | Diffuse | Yes | No | Octreotide ➔ Surgical resection | Died d/t uncontrolled symptoms |
MacLean et al. (2002) [27] | 14 yr. | 3 | Extensive | Diffuse | Yes | No | Octreotide➔ Tranexamic acid | Clinical improvement |
D Prasad et al. (2019) [29] | N = 2, age 2–18 yr. | 2 | Diffuse intestine | Diffuse | No | No | Octreotide | Clinical improvement |
N = 4, age 1–10 yr. | 3 | Extensive | Diffuse | Yes | No | Octreotide + Tranexamic acid | Clinical improvement | |
Ozeki et al. (2016) [20] | 12 yr. | 3 | Extensive | Diffuse | Yes | No | Propranolol➔Everolimus | Remission for 12 months |